| Oct 26 |
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
|
| Oct 25 |
Apellis a new sector perform at RBC on Syfovre expectations
|
| Oct 22 |
Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results
|
| Oct 16 |
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
|
| Oct 16 |
Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
|
| Oct 4 |
Apellis: Weighing Syfovre's Rapid Expansion Against Risks In The GA Market (Rating Upgrade)
|
| Oct 3 |
Should You Hold Apellis Pharmaceuticals (APLS)?
|
| Oct 1 |
Apellis Pharmaceuticals: Assessing The Impact Of The Negative CHMP Opinion
|
| Sep 25 |
Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
|
| Sep 23 |
Apellis Stock Down as Eye Drug Faces Third CHMP Rejection in the EU
|
